BoneScalpel™ Workshop Draws More Than 70 Surgeons At IMAST Meeting

Jul 21, 2015, 08:00 ET from Misonix, Inc.

FARMINGDALE, N.Y., July 21, 2015 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, hosted a successful BoneScalpel Hands-On Workshop during the International Meeting on Advanced Spine Technologies ("IMAST") in Kuala Lumpur, Malaysia last week.  More than 70 surgeons attended the workshop and were trained on advanced spine surgical techniques utilizing the BoneScalpel.

"We are extremely pleased to see this degree of interest from international spine surgeons.  The key opinion leaders that presented at this year's workshop focused on the clinical benefits of using the BoneScalpel and prepared the workshop attendees for future use in their own practices.  Training this many surgeons at one event is an exciting way to kick off our new fiscal year," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.

The Ultrasonics in Spine Surgery: BoneScalpel Hands-On Workshop was moderated and facilitated by the following group of leading spine surgeons:

  • Dr. Peter Newton, Rady Children's Hospital in San Diego, CA;
  • Dr. Juan Uribe, University of South Florida in Tampa, FL; and
  • Dr. Greg Mundis, Scripps Memorial Hospital in La Jolla, CA.

The surgeon presenters discussed their surgical techniques and clinical evidence on the application of the BoneScalpel in Minimally-Invasive Spine Surgery, AIS Posterior Release, Cervical Laminoplasty and other degenerative procedures.

The faculty agreed that the use of the BoneScalpel leads to a safer, more efficient surgical experience with repeatable reduction in blood loss and an increase in the amount of viable autogenous bone graft harvested. Dr. Juan Uribe commented on his experience in adopting the technology, "I was immediately enthused by the added safety offered by the BoneScalpel when cutting bone near the dura and nerves.  In my minimally-invasive, transforaminal lumbar interbody fusion (tlif) procedures, I have achieved surgical efficiencies, safer facectomies, less blood loss and more viable autograft bone."

Dr. Greg Mundis explained, "Adding the BoneScalpel to my procedures has positively impacted my surgical practice.  For example, when I perform a deformity correction, my patients will now lose less blood, need fewer transfusions and go to the recovery room faster than they had in the past."

"It was easy to recognize the clinical value that the BoneScalpel brings to spine surgery within the first few cases of using it.  It allows me to remove bone safely and reduce blood loss.  We now use it in every deformity procedure," concluded Dr. Peter Newton.

The IMAST meeting is a three-day international forum with leading spine surgeons discussing and demonstrating innovative surgical technologies that help improve patient care. This year's meeting was attended by over 775 delegates.

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Corporate Contact

Investor Contact

Richard Zaremba

Joe Diaz

Chief Financial Officer

Lytham Partners                                




SOURCE Misonix, Inc.